OpenAI’s advertising business grows slowly
Translated from German and summarized by DistantNews. Read the original for the full story.
At a glance
- OpenAI said annualized revenue from its ChatGPT Ads platform has exceeded $1 billion and is expanding to advertisers across Europe, India, the Middle East and North Africa.
- Analyst Nate Elliott called the figure both impressive and disappointing, saying it could indicate that OpenAI will miss its $2.5 billion advertising-revenue target for 2026.
- OpenAI is using advertising to challenge Alphabet and Meta and support its planned U.S. initial public offering, which could take place in 2027 or earlier.
OpenAI’s ChatGPT advertising business has passed $1 billion in annualized revenue, but the milestone still leaves the company far from its stated target for 2026.
OpenAI said companies can now book advertisements directly through a dedicated tool in Europe, India, the Middle East and North Africa. In the United States, the platform has so far attracted mainly small and medium-sized businesses, which now account for a substantial share of the advertising operation.
The new figures drew a sharply divided assessment from Nate Elliott, an analyst at research firm Emarketer. He described them as “incredibly impressive and terribly disappointing.” In his view, the $1 billion figure suggested that OpenAI could miss its $2.5 billion advertising-revenue goal for 2026.
Advertising puts OpenAI in competition with Alphabet and Meta, whose annual advertising revenues reach hundreds of billions of dollars. OpenAI hopes the business will also support a planned U.S. stock-market listing. The company filed a confidential application for an initial public offering this year, and a debut is expected in 2027 or earlier.
Incredibly impressive and terribly disappointing.
Originally published by Die Presse in German. Translated, summarized, and contextualized automatically by DistantNews, with a note on how the source frames the story. Not individually reviewed before publishing. How this works.